the drug to stay in the market, due to a lack of adverse events, and a critical need for the product. Supplies of Fabrazyme, Genzyme's treatment for Fabry disease, have been rationed to one-third the recommended dose prompting patients to file a petition asking for a license to produce Fabrazyme by other manufacturers to make up the deficit under the Bayh–Dole Act. Products Aldurazyme Alprolix Aubagio Cablivi Cerdelga Cerezyme Clolar Dupixent Elitek Eloctate Eloxatin Fabrazyme Jevtana Kevzara Lemtrada Libtayo Lumizyme Sarclisa Taxotare Zaltrap Lobbying Genzyme has spent more than $8.2 million on lobbying from 2007 to 2009. In 2009 alone, it had 10 different organizations with a total of 49 lobbyists working on its behalf. Takeover bid On August 30, 2010, Sanofi announced a bid to acquire Genzyme for $18.5 billion. The deal was later rejected by the board of Genzyme. On February 16, 2011, Sanofi declared the full acquisition of Genzyme for $20.1 billion. Lawsuit over marketing of Seprafilm In September 2015, Genzyme accepted responsibility and agreed to pay $32.59 million over U.S. charges against its marketing of the adhesion barrier product Seprafilm. Genzyme's sales representatives had been instructing surgeons on how to create a "slurry" using Seprafilm for use during laparoscopic surgeries. This use of Seprafilm is not FDA-approved. Genzyme had also reached a $22.28 million civil agreement pertaining to marketing of Seprafilm in December 2013. Genzyme was claimed to be in violation of the federal False Claims Act. References External links Schouten, E. "Genzyme’s lifelong commitments". NRC Handelsblad. November 24, 2005. https://web.archive.org/web/20060924143610/http://www.gaucher.org.uk/cercer.htm Hirehealth’s website <https://web.archive.org/web/20061029102247/http://www.hirehealth.com/Public/CompanyDetails.aspx?COMPANY_ID=44719> Riskind. P. Multiple Sclerosis—The immune system’s terrible mistake. Fall 1996, Vo. 5, No. 4. Hoovers’ website <http://www.hoovers.com/genzyme/--ID__13560--/free-co-factsheet.xhtml> Calabro, S. "Genzyme put patients first, and grew to become a multi-billion-dollar company. But empires don't survive on altruism." Pharmaceutical Executive, [March 1, 2006] <http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=310976&&pageID=7&searchString=genzyme> Genzyme corporate website OpenSecrets profile Sanofi Pharmaceutical companies established in 1981 Biotechnology companies of the United States Companies based in Cambridge, Massachusetts Health care companies based in Massachusetts Biotechnology companies established in 1981 Companies formerly listed on the Nasdaq National Medal of Technology recipients Orphan drug companies 1981 establishments in Massachusetts 1980s initial public offerings 2011 mergers and acquisitions American subsidiaries of foreign companies